GENTIAN DIAGNOST. NO -,01

GENTIAN DIAGNOST. NO -,01 Share · NO0010748866 · A2DLP7 (XOSL) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak

Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of GENTIAN DIAGNOST. NO -,01
No Price
Closing Price XOSL 30.04.2026: 44,60 NOK
30.04.2026 14:25
Current Prices from GENTIAN DIAGNOST. NO -,01
ExchangeTickerCurrencyLast TradePriceDaily Change
XOSL: OSLO BORS
OSLO BORS
GENT.OL
NOK
30.04.2026 14:25
44,60 NOK
-
XDUS: Düsseldorf
Düsseldorf
GDASAN66.DUSB
EUR
30.04.2026 06:12
3,66 EUR
-
XDQU: Quotrix
Quotrix
GDASAN66.DUSD
EUR
30.04.2026 05:27
3,74 EUR
-
Share Float & Liquidity
Free Float 50,33 %
Shares Float 7,78 M
Shares Outstanding 15,46 M
Company Profile for GENTIAN DIAGNOST. NO -,01 Share
Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, and the United States. It offers in-vitro diagnostic reagents for clinical chemistry analyzers. The company's products include the gentian calprotectin immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Cystatin C, a superior GFR marker for the diagnosis and therapeutic control of renal function; NT-proBNP Immunoassay for diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure; and Canine c-reactive protein (CRP) immunoassay, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine CRP in dog plasma and serum. It also provides turbidimetric SARS-CoV-2 total antibody immunoassay, a quantitative antibody test for detecting antibodies targeting the S1-subunit. The company was incorporated in 2001 and is headquartered in Moss, Norway.

Company Data

Name GENTIAN DIAGNOST. NO -,01
Company Gentian Diagnostics ASA
Website https://www.gentian.com
Primary Exchange XOSL Frankfurt
WKN A2DLP7
ISIN NO0010748866
Asset Class Share
Sector Healthcare
Industry Medical - Devices
CEO Matti Heinonen
Market Capitalization 689 Mio
Country Norway
Currency EUR
Employees 0,1 T
Address Bjørnåsveien 5, 1596 Moss
IPO Date 2016-12-14
Dividends from 'GENTIAN DIAGNOST. NO -,01'
Ex-Date Dividend per Share
07.05.2025 0,40 NOK

Ticker Symbols

Name Symbol
OSLO BORS GENT.OL
Düsseldorf GDASAN66.DUSB
Frankfurt 6FK.F
Quotrix GDASAN66.DUSD
More Shares
Investors who hold GENTIAN DIAGNOST. NO -,01 also have the following shares in their portfolio:
EURO GOVERNMENT BOND INDEX FUND - GBP HEDGED ACC
EURO GOVERNMENT BOND INDEX FUND - GBP HEDGED ACC Fund
PEIJIA MEDICAL
PEIJIA MEDICAL Share